Bi-weekly administration of gemcitabine plus vinorelbine in elderly patients with advanced non-small-cell lung cancer: multicenter phase II trial |
| |
Authors: | Araya Tomoyuki,Kasahara Kazuo,Kimura Hideharu,Shibata Kazuhiko,Kita Toshiyuki,Shirasaki Hiroki,Hara Johsuke,Yoshimi Yuzo,Sone Takashi,Oribe Yoshitaka,Nobata Kouichi,Nishi Kouichi,Fujimura Masaki,Nakao Shinji Kanazawa Lung Cancer Chemotherapy Group |
| |
Affiliation: | Respiratory Medicine, Kanazawa University Hospital, Takara-machi 13-1, Kanazawa 920-8641, Japan. |
| |
Abstract: | PURPOSE: Gemcitabine (GEM) and vinorelbine (VNR) have demonstrated activity as a first-line treatment in elderly patients with advanced non-small-cell lung cancer (NSCLC). We conducted a multicenter phase II trial to evaluate the efficacy and toxicity of bi-weekly administration of GEM plus VNR in elderly patients with advanced NSCLC. PATIENTS AND METHODS: Forty-six chemotherapy-naive elderly (age: >or=70 years) NSCLC patients were enrolled. Patients were eligible if they had histologically or cytologically confirmed unresectable NSCLC with measurable and/or assessable disease. Patients received GEM (1000 mg/m2) and VNR (25 mg/m2) every 2 weeks. RESULTS: The objective response rate of this treatment was 22.7% (95% confidence interval (CI), 10.3-35.1%), median survival time was 310 days, and median time to progression was 133 days. The one-year survival rate was 40.9% (95% CI, 26.3-55.4%), and most adverse events were mild. Only three (6.8%) patients needed to omit GEM because of grade 4 neutropenia or due to physician judgment. No patients suffered treatment-related death. CONCLUSIONS: Bi-weekly administration of GEM plus VNR in elderly patients was an effective, feasible and well-tolerated treatment schedule. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|